J. Jani

发表

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).

J. Isaacs, C. Murakata, T. Angeles, 1999, Cancer research.

Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design

P. Wei, T. Smeal, N. Hosea, 2010, Molecular Cancer Therapeutics.

Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

Matthew D. Wessel, Jing Lin, M. Wessel, 2008, Cancer research.

Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family.

S. Srimatkandada, J. Lazo, S. Sebti, 1989, Biochemistry.

Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice.

S. Sebti, J. Jani, G. Tkalcevic, 1991, Cancer communications.

In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64.

J. Lazo, S. Sebti, J. Mistry, 1992, Oncology research.

Desensitization of 5HT2 Receptors by Protein Kinase C Activation in Distal Pulmonary Vascular Smooth Muscle Cells in Culture

S. Sebti, B. Pitt, I. Reynolds, 1994, Microcirculation.

PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy

L. Pustilnik, J. Christensen, B. D. Cohen, 2010, Molecular Cancer Therapeutics.

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

F. Rastinejad, W. Roberts, Eugenia Floyd, 2003, Cancer research.

In vivo circumvention of human colon carcinoma resistance to bleomycin.

J. Lazo, S. Sebti, J. Mistry, 1992, Cancer research.

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line

Zhou Zhu, A. Blasina, T. Vanarsdale, 2013, Frontiers of Medicine.

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

J. Christensen, S. Bender, R. Schwab, 2013, PloS one.

NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells

R. Hromas, A. Jaiswal, S. Narayan, 2015, PloS one.

Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis.

S. Specht, S. Singh, J. Jani, 1993, Invasion & metastasis.

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.

L. Pustilnik, P. Miller, J. Kath, 2003, Cancer research.

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.

R. D. Connell, L. Pustilnik, Joel Morris, 2007, Cancer research.

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

N. Neff, J. Isaacs, A. M. Camoratto, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comparison of radiotherapy alone and radiotherapy with chemotherapy using adriamycin and 5-fluorouracil in bronchogenic carcinoma.

C. Smith, J. Jani, T. Deeley, 1981, Thorax.

Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine

Bing-he Xu, M. Levitt, Shivendra V. Singh, 2004, Cancer Chemotherapy and Pharmacology.

Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621

G. Karam, J. Lapointe, J. Xu, 2012, mAbs.

Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.

H. Zaren, S. Singh, J. Jani, 1995, Cancer letters.

CEP‐751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti‐tumor activity

N. Neff, J. Isaacs, A. Maroney, 1997, International journal of cancer.

The Biological and Biochemical Effects of CP-654577 , a Selective erbB 2 Kinase Inhibitor , on Human Breast Cancer Cells

L. Pustilnik, P. Miller, J. Kath, 2003 .

Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells.

J. Lazo, S. Sebti, J. Mistry, 1991, Biochemical pharmacology.

Metabolic inactivation: a mechanism of human tumor resistance to bleomycin.

J. Lazo, S. Sebti, E. Gorelik, 1991, Cancer research.

Modulation of cisplatin sensitivity and accumulation by interferon α‐2A in human squamous carcinoma cell lines

Shivendra V. Singh, H. Zaren, H. Xia, 1995, International journal of cancer.

Mechanism of cross‐resistance to cisplatin in a mitomycin C‐resistant human bladder cancer cell line

Bing-he Xu, Shivendra V. Singh, S. Specht, 1995, International journal of cancer.

Synthesis and Evaluation of Fluoromycin: A Novel Fluorescence-labeled Derivative of Talisomycin Siot,1

J. Lazo, S. Sebti, R. Mujumdar, 2006 .

Abstract A86: Design, synthesis, and SAR of focal adhesion kinase (FAK) inhibitors

Matthew D. Wessel, Jing Lin, K. Coleman, 2009 .